

April 5, 2022

Escala Medical % Jonathan Kahan Partner Hogan Lovells 555 Thirteenth Street, NW Washington, DC 20004-1109

Re: K213783

Trade/Device Name: Apyx

Regulation Number: 21 CFR§ 884.4530

Regulation Name: Obstetric-Gynecologic Specialized Manual Instrument

Regulatory Class: II Product Code: PBQ Dated: February 28, 2022 Received: February 28, 2022

Dear Jonathan Kahan:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies.

You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/training-and-continuing-education/cdrh-learn) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice">https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Jason R. Roberts, Ph.D.
Assistant Director
DHT3B: Division of Reproductive,
Gynecology and Urology Devices
OHT3: Office of GastroRenal, ObGyn,
General Hospital and Urology Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indications for Use

Form Approved: OMB No. 0910-0120 Expiration Date: 06/30/2023

Expiration Date: 06/30/2023 See PRA Statement below.

510(k) Number (if known)		
K213783		
Device Name		
Арух		
Indications for Use (Describe)		
The Apyx is intended for attaching sutures to ligaments of the pelvic floor.		
Type of Use (Select one or both, as applicable)		
Prescription Use (Part 21 CFR 801 Subpart D)	Over-The-Counter Use (21 CFR 801 Subpart C)	

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

CONTINUE ON A SEPARATE PAGE IF NEEDED.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

510(k) SUMMARY Escala Medical Apyx (K213783)

Submitter

Escala Medical Ltd.

17 Tchelet St.

Misgav Business Park, 2017400

Israel

Phone: +972.72.260.7000

Contact Person: Edit Goldberg

Date Prepared:

April 4, 2022

Name of Device:

Арух

Common or Usual Name:

Fixation device for the pelvic floor

Classification Number:

884.4530

Classification Name:

Obstetric-gynecologic specialized manual instrument

Regulatory Class:

2

Product Code:

PBQ

Product Code Name:

Fixation, Non-Absorbable or Absorbable, For Pelvic Use

Predicate Device:

POP Medical Solutions, NeuGuide, K160569

The predicate device has not been subject to a device design-related recall.

Device Description

The Apyx device is indicated for anchoring sutures to ligaments of the pelvic floor. The device consists of an implantable nitinol anchor with 4 prongs configured with either non-absorbable or resorbable suture. The anchor-suture assembly is contained within a cartridge, wherein the anchor/suture assembly is deployed to the target site from the cartridge with an applicator. An optional retriever can be used to remove the anchor in the event of sub-optimal placement of an Anchor during the index procedure.

The Apyx device is a single use device which is supplied sterile.

Intended Use / Indications for Use

The Apyx is intended for attaching sutures to ligaments of the pelvic floor.

Summary of Technological Characteristics

Both the subject and predicate devices are indicated for attaching sutures to ligaments of the pelvic floor. The technological characteristics of the Apyx are comparable to that of the NeuGuide predicate. Both devices comprise a nitinol anchor, which is provided with suture and delivered via an applicator. The devices are further each supplied sterile and are preloaded with the anchor-suture assembly. The minor differences between the design of the devices do not raise different questions of safety or effectiveness and the performance testing demonstrates comparable performance compared to the predicate.

	Арух	NeuGuide (K160569)
Anchor design	4 prongs	2 prongs
Anchor materials	Nitinol	Nitinol
Suture	Polypropylene or Polydioxanone	Polypropylene monofilament
Applicator	Yes – shaft (applicator cartridge) and handle	Yes – shaft and thimble
Retriever for device removal	Yes	No

Table 1: Summary of Technological Characteristics

Performance Data

- Biocompatibility testing in accordance with ISO 10993 consistent with intended duration of contact:
 - Cytotoxicity
 - Sensitization
 - Pyrogenicity
 - Irritation
 - Intracutaneous reactivity
- Chemical characterization and toxicological risk assessment in accordance with ISO 10993-18 to address biocompatibility endpoints of:
 - Genotoxicity
 - Acute systemic toxicity
 - Chronic systemic toxicity
 - Carcinogenicity
 - Developmental/reproductive toxicity
- Sterilization validation per ISO 11135
- Packaging validation
- Shelf-life validation
- Dimensional verification
- Anchor fracture resistance
- Anchor fixation pull out
- Suture detachment
- Suture tensile strength
- MRI compatibility
- Corrosion resistance per ASTM F2129
- Bond strength

Cadaver Testing

Cadaver model testing was conducted to demonstrate that the Apyx instructions for use and critical operation tasks can be performed. Following the system instructions, users delivered the anchor through a transvaginal approach and then retrieved the applied anchors from their implantation site. No complications or unanticipated risks were observed throughout all anchor delivery and retrieval procedures. All anchors were accurately delivered into the target

ligament and no damage to any of the surrounding structures was observed. It was therefore concluded that the Apyx device meets the design requirements and is suitable for its intended use.

Conclusion

The Apyx is as safe and effective as the POP Medical Solutions, NeuGuide, K160569. The Apyx has the same intended use and similar indications, technological characteristics, and principles of operation as its predicate device. The minor technological differences between the Apyx and its predicate devices raise no new issues of safety or effectiveness. Performance data demonstrates that the Apyx is as safe and effective as the NeuGuide predicate to support a substantial equivalence determination.